Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis

BACKGROUND: Revefenacin, a once-daily, long-acting muscarinic antagonist delivered via standard jet nebulizer, increased trough forced expiratory volume in 1 s (FEV(1)) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) in prior phase 3 trials. We evaluated the eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Donohue, James F., Kerwin, Edward, Barnes, Chris N., Moran, Edmund J., Haumann, Brett, Crater, Glenn D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216337/
https://www.ncbi.nlm.nih.gov/pubmed/32393215
http://dx.doi.org/10.1186/s12890-020-1156-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216337/
https://www.ncbi.nlm.nih.gov/pubmed/32393215
http://dx.doi.org/10.1186/s12890-020-1156-4

Ejemplares similares